Old DAT / New Data : Positive Direct Antiglobulin Test
Quinquenel A, Al Nawakil C, Baran-Marszak F, et al.
Key Points:
- Investigators aimed to explore clinical and biological characteristics and outcome of CLL patients showing a positive direct antiglobulin test at any time during the course of disease
- 10% patients had at least one positive DAT, only 35% of them developed symptomatic AIHA
- Symptomatic AIHA had no impact on treatment free survival or overall survival compared with cases with positive DAT only
- 82% of cases harbored unmutated IGHV, and CD38 was expressed in 60% cases
- 41 (76 %) patients required treatment at 85 months
- Median time to first treatment was very short (16 months), and the median overall survival of this cohort was 84 months
- IGHV unmutated stage A DAT positive cases had shorter time to first treatment (26 months) and reduced median overall survival (55 months) when compared with DAT negative cases
Implications:
- Positive DAT at any time of course of CLL is associated with poor outcome and has same adverse prognostic impact as onset of symptomatic AIHA.
View the original abstract on the ASH website.
